Banco Santander S.A. (SAN) – Company Press Releases
-
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, A LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
-
Santander US Survey Finds Optimism Rising Among Middle-Income Households as Concerns about Inflation and Recession Ease
-
ROSEN, A LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
Santander Names Swati Bhatia Head of Retail Banking and Transformation
-
ROSEN, A LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
Banco Santander Chile Announces Redemption of Notes
-
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
-
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
-
SAN INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN
-
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
-
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
-
The Santander Chile subsidiary Santander Consumer signs agreement to acquire Mundo Crédito's auto loan portfolio
-
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
-
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
-
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
-
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
-
Santander US Middle-Income Survey Finds Majority of Americans Remained Optimistic in 2023, See Headwinds Ahead in 2024
-
Banco Santander Chile: Announces Fourth Quarter 2023 Analyst and Investor Webcast / Conference Call
-
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
-
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
-
Santander Closes on Transaction with the FDIC to Service Signature Bank's Multifamily Real Estate Assets
-
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
-
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
-
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alon
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
-
Santander Bank Introduces New Essential Checking Account
-
Birchway Tropicana Aims to Bring High Quality Living at Value Pricing to Las Vegas
-
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
-
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
-
Santander US Paths to Prosperity Research Finds Consumers Resilient Though Pressures Mounting
-
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
-
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
-
Santander Bank Unifies U.S. Commercial Businesses, Names Michael Lee Head of Commercial Banking
-
GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
-
Sanofi Bridging the Gap between the Homeless and Society via Futsal
-
Banco Santander Chile: Announces Third Quarter 2023 Analyst and Investor Webcast / Conference Call
-
Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
-
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
-
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
-
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Back to SAN Stock Lookup
